Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/156082
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Díaz, Marta | - |
dc.contributor.author | Gallego Escuredo, José Miguel | - |
dc.contributor.author | López Bermejo, Abel | - |
dc.contributor.author | Zegher, Francis de | - |
dc.contributor.author | Villarroya i Gombau, Francesc | - |
dc.contributor.author | Ibáñez, Lourdes | - |
dc.date.accessioned | 2020-04-20T14:42:27Z | - |
dc.date.available | 2020-04-20T14:42:27Z | - |
dc.date.issued | 2018-07-19 | - |
dc.identifier.issn | 1687-8337 | - |
dc.identifier.uri | http://hdl.handle.net/2445/156082 | - |
dc.description.abstract | BACKGROUND: Fetuin-A is a glycoprotein produced in the liver and related to metabolic syndrome; fetuin-A secretion is divergently regulated in different pathological conditions. In girls with polycystic ovary syndrome (PCOS), insulin sensitization results in a more favorable endocrine-metabolic outcome than oral contraception; we assessed whether those differences are underscored by changes in circulating fetuin-A. METHODS: Fetuin-A concentration endocrine-metabolic markers and hepatovisceral fat were measured longitudinally in 35 PCOS girls [age, 16 yr; body mass index (BMI), 23 kg/m2] randomized to receive either oral contraception [ethinylestradiol-levonorgestrel (n = 18)] or a low-dose combination of spironolactone, pioglitazone, and metformin (SPIOMET, n = 17) over 12 months. Healthy adolescent girls (age- and BMI-matched) were used as controls (n = 25). RESULTS: Pretreatment fetuin-A serum levels in PCOS girls were lower than those in controls. After 12 months on treatment, fetuin-A raised to control levels only in the SPIOMET subgroup (P = 0.009, versus oral contraception); this increase was paralleled by a healthier metabolic profile with less hepatic fat (by MRI); baseline serum fetuin-A as well as the changes over 12 months was inversely related to hepatic adiposity. CONCLUSIONS: A low-dose combination of insulin sensitizers and an antiandrogen-but not oral contraception-normalizes fetuin-A levels in adolescent girls with PCOS. This trial is registered with ISRCTN29234515. | - |
dc.format.extent | 5 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Hindawi | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1155/2018/4192940 | - |
dc.relation.ispartof | International Journal Of Endocrinology, 2018, vol. 2018 | - |
dc.relation.uri | https://doi.org/10.1155/2018/4192940 | - |
dc.rights | cc-by (c) Díaz, Marta et al., 2018 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) | - |
dc.subject.classification | Malalties de l'ovari | - |
dc.subject.classification | Endocrinologia | - |
dc.subject.classification | Noies adolescents | - |
dc.subject.other | Ovary diseases | - |
dc.subject.other | Endocrinology | - |
dc.subject.other | Teenage girls | - |
dc.title | Low-dose spironolactone-pioglitazone-metformin normalizes circulating fetuin-a concentrations in adolescent girls with polycystic ovary syndrome | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 683420 | - |
dc.date.updated | 2020-04-20T14:42:28Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 30123261 | - |
Appears in Collections: | Articles publicats en revistes (Bioquímica i Biomedicina Molecular) Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
683420.pdf | 886.01 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License